Clinical trials: First Line Treatment
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
C10.114.375.500
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
The study design matches with a multicenter observational ambispective study. A first pilot study will be undertaken in Caen center and is expected to be extended to Rouen and Lille center.
- Trial name
- PREMISEP (NCT03308994)
- Testing
- Delay between MS onset and introduction of first line DMT, EDI
- Where
- 4 sites in France
- Volunteers
- 650 people
- Sponsor
- University Hospital, Caen
Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment…
- Conditions
- Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain
- Trial name
- NCT07326137
- Testing
- First-Line Systemic Therapy, Celiac Plexus Neurolysis (CPN)
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Tongji Hospital
Aplastic Anemia
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
RATIONALE: Immunosuppressive therapies, such as anti-thymocyte globulin and cyclosporine, may improve bone marrow function and increase blood cell counts.
- Trial name
- NCT01231841
- Testing
- cyclosporine, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Chronic Lymphocytic Leukemia, CLL
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC).
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line
- Trial name
- NCT00628238
- Testing
- Lenalidomide and Rituximab
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chronic Lymphocytic Leukemia Research Consortium
Acute Promyelocytic Leukemia
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options…
- Trial name
- NCT02938858
- Where
- 27 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Hypertension, Cardiovascular Disease
Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.
- Trial name
- ARBACE (NCT01152567)
- Where
- 56 sites in Sweden
- Volunteers
- 50,000 people
- Sponsor
- AstraZeneca
Breast Cancer, Neutropenia
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00002866
- Testing
- filgrastim, docetaxel, epirubicin hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 50 people
- Sponsor
- NCIC Clinical Trials Group
Synovial Sarcoma, Cancer
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
- Conditions
- Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma
- Trial name
- NCT03520959
- Testing
- LV305, G305
- Where
- 29 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Uveitis
First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
The proposed study is a masked trial, with stratified block randomization by site, designed to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line steroid-sparing treatment for…
- Trial name
- FAST (NCT01232920)
- Testing
- Methotrexate, Mycophenolate mofetil
- Where
- 2 sites in India
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Infantile Spasms
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
Infantile Spasms, is an rare age-specific epilepsy of early infancy. A 2012 American Academy Neurology/ Child Neurology Society practice parameter update on the medical treatment of infantile spasms concluded…
- Trial name
- PREDVGB (NCT02299115)
- Testing
- Prednisolone, Vigabatrin
- Where
- Canada
- Sponsor
- The Hospital for Sick Children
Metastatic Colorectal Cancer
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer
This is a clinical trial investigating the effectiveness and safety of the combination of the study drugs bevacizumab and AMG386 in patients with advanced (metastatic) chemotherapy-naive bowel (colorectal) cancer.
- Trial name
- Vengeance (NCT01249521)
- Testing
- AMG386 and bevacizumab
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Austin Health
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Metastatic Colorectal Cancer
Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab
-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients.
- Trial name
- PROVETTA (NCT01363739)
- Where
- Italy
- Volunteers
- 265 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Prostate Cancer
Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer
Study design: The study is a two arm randomised controlled trial (randomisation ratio 1:1) comparing an aerobic exercise training intervention to usual care plus exercise advice.
- Trial name
- PANTERA (NCT02409212)
- Testing
- Aerobic exercise training
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
aGVHD
Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease
Allogenic haemopoietic stem cell transplantation (allo-HSCT) is the effective treatment for many hematologic malignancies and some non-malignant diseases.
- Trial name
- NCT05531266
- Testing
- hUC-MSCs, glucocorticoids
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- DOSE (NCT00710619)
- Testing
- activated recombinant human factor VII, Feiba VH
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of…
- Trial name
- NCT04974398
- Testing
- Penpulimab
- Where
- 56 sites in United States, Australia and 3 more
- Volunteers
- 296 people
- Sponsor
- Akeso
Neonatal Abstinence Syndrome
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of…
- Trial name
- NCT03092011
- Testing
- Clonidine, Morphine Sulfate
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- The Cooper Health System
Hand Osteoarthritis
Outcomes After First-line Treatment of Hand Osteoarthritis
This study will investigate outcomes of a 3-month first-line treatment program for hand osteoarthritis, using data from the Swedish Osteoarthritis Registry.
- Trial name
- NCT07708454
- Testing
- 3 months of exercise and education
- Volunteers
- 2,000 people
- Sponsor
- Lund University